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SYSTEM AND METHODS FOR

associated with significant complications, sometimes addi

VENTILATION THROUGH A BODY CAVITY

tional therapies are required such as the use of anticoagu
lants ( heparin is standard ). However, anticoagulants are

CROSS REFERENCE TO RELATED

often administered to the patient leading to additional
5 adverse side effects . Additionally , ECMO is expensive and
complex to operate , limiting its accessibility for emergency
This application claims the benefit of U . S . provisional care.
applications 61/813 ,626 filed Apr. 18 , 2013 , which is incor
Because of the high mortality rate, methods of bypassing
porated by reference herein in its entirety.
the lungs and delivering oxygen directly to the body have
been explored for many years . Research has focused on
FEDERAL FUNDING
APPLICATIONS

peritoneal oxygenation as a method of extrapulmonary res

This invention was made with government support under
grant number CBET1059726 awarded by the National Sci

piration . The exchange of oxygen and carbon dioxide occurs

through the large surface area of the membrane that lines the
abdominal cavity, the peritoneum .
ence Foundation . The government has certain rights in the 15 Previous methods include in situ extrapulmonary venti
invention .

FIELD OF THE INVENTION

lation (EV ). Success in oxygenating blood in situ has been
achieved by circulating fluorocarbons, blood , and liposome
encapsulated hemoglobin (a synthetic oxygen carrier )

The invention relates generally to the delivery of oxygen 20 through the intraperitoneal ( IP ) space , or cavity . Additional
to a subject. More particularly, the invention relates to the previous methods include the study of carriers for the

delivery of oxygen through a body cavity of a subject using

delivery of oxygen . Carriers have included blood , perfluo

rocarbon (PFC ), and synthetic hemoglobin carriers , for
oxygen microbubbles .
example TRM -645 , which are effective . In contrast, pure
BACKGROUND OF THE INVENTION
25 oxygen gas has been shown not to be an effective carrier.
None of the effective carriers, however, are both safe and
Oxygen is one of the basic essentials for sustaining life . economical. For example , PFCs are expensive to generate

Today 's medical technology can supply oxygen to patients
and evaporate into potent greenhouse gases creating a sig
experiencing pulmonary failure , otherwise known as respi - nificant environmental concern . They are also very stable ,
ratory failure . Pulmonary failure occurs when the lungs 30 tending to accumulate in biological systems in which they
experience significant damage and are unable to supply the
are used . Blood and products derived from blood (like

body and brain with oxygen . Pulmonary failure may be

synthetic hemoglobin carriers ) suffer from scarcity and are

caused by a variety of conditions including , for example ,

relatively expensive to fabricate and store . Furthermore , EV

lung cancer, physical trauma, acute respiratory distress syn
ventilation requires high volumes of perfusate ; therefore, a
drome (ARDS ), aerosolized bioterrorism agents, and dis- 35 fluid that is economical and biodegradable is important. In
eases such as severe acute respiratory syndrome (SARS), additional, none of the previously developed methods have

pneumonia, tuberculosis, sepsis, and other bacterial or viral
infections, physical trauma, and chemical or smoke inhala tion . Currently , oxygen can be supplied to patients experi-

achieved certain components for extrapulmonary respira
tion : ( 1 ) delivery of an adequate supply of oxygen, ( 2 )
long -term safety for the patient, and (3 ) cost- effectiveness.

MV has been an ineffective method for delivering oxygen

of a phospholipid monolayer. The phospholipid monolayer

encing pulmonary failure through mechanical ventilation 40 Another form of therapy explored to deliver oxygen
(MV ) or extracorporeal membrane oxygenation (ECMO ).
systematically by circulating it through the IP space is a
However, the mortality rate of patients receiving oxygen
method that uses an oxygen microbubble (OMB ) carrier.
through MV or ECMO remains high .
OMBs are oxygen filled bubbles that have a shell composed

to the body in certain cases because oxygen exchange is 45 shell of an OMB has similar composition to lung surfactant

decreased by damage to the lung and because of increased
stress caused to the injured lung by the treatment. As an
example, for patients experiencing severe hypoxemia arising

and requires comparable physical properties, such as rapid
adsorption to and mechanical stabilization of the gas/liquid
interface and high gas permeability . Thus OMBs are also

from lung injury MV may be inadequate owing to limited

designed to mimic the mechanical and gas transport prop

mass transfer in the injured lung; over -inflation , barotrauma 50 erties of the alveolus to deliver the oxygen payload and
and cyclic closing and reopening of the alveoli may further uptake carbon dioxide .

damage the lung and trigger a pulmonary and systemic
stem
inflammatory reaction that may lead to multiple system

Previous research has focused on the delivery of OMBS
through intravenous ( IV ) oxygen delivery. However, IV
organ failure .
injection of OMBs is a one -way administration and does not
ECMO is a temporary artificial extracorporeal support of 55 allow for the circulation of microbubbles into and out of the
the respiratory system and /or cardiac system . ECMO was body to both deliver oxygen and remove carbon dioxide .
first used in an adult in 1972 to treat severe respiratory Delivering oxygen using and IV appears to be a promising

failure and in 1974 on the first newborn . Innovations in
ECMO include the introduction of polymethylpentene hol-

method for short-term rescue, but the prolonged continuous
infusion of oxygen microbubbles into the bloodstream poses

low fibers with non thrombogenic coatings and thin wire - 60 significant challenges for clinical translation , including the

reinforced cannula walls . ECMO use has historically cen tered on neonatal care . However, ECMO is an expensive

alternative therapy with limited availability in hospitals and

potential for embolism , thrombosis , immunogenicity and
toxicities of lipid and saline load . For example , with IV

injection of OMBs, any oxygen inspired through the lungs

length of treatment. ECMO is able to bypass the injured
can be absorbed by the microbubbles and can cause long
lungs to deliver oxygen and allow the lungs to heal, however 65 circulating bubbles that may cause embolism or other prob

there is a high risk of thrombosis and contamination of the

lematic conditions, such as those observed in decompression

blood because it is removed from the body . Since ECMO is

sickness. Further, with the potential for embolism , IV injec

US 10 , 124 ,126 B2
tion of microbubbles requires a strict upper limit on the
microbubble size (< 10 micrometers ) and on the microbubble

lung injury , respiratory distress , cardiac arrest, or other
situations in which lung function is sub - optimal. The inven
tion also precludes the need for an extracorporeal loop , thus

volume fraction (<70 % ).
Still another problem with IV injection of OMBs is that

potentially circumventing the complications of thrombosis

microbubbles will exchange oxygen for nitrogen . The nitro
gen - containing microbubbles will be persistent, which can
lead to serious problems, such as those observed during

or even supplanting ECMO , may significantly reduce the
cost and complexity of EV .
The ability to deliver oxygen via a body cavity may also

severe morbidity and death ). In addition , intravenous oxy genation using OMBs cannot support long-term ventilation
due to the lipid and saline load from continuous infusion .
A demand therefore exists for a system and method for

severe hypoxia of any origin ( due to airway obstruction or
due to other causes ) results in irreversible brain injury within
minutes . Administration of readily accessible oxygen - bear
ing microbubbles may prevent the morbidity and mortality

efficient than the current systems and methods presently
available . The invention satisfies this demand .

human subjects. In addition , subjects suffering from lung

any nitrogen inspired through the lungs , such as that found 5 and immune reaction presented by the artificial surfaces
in air, will be absorbed by the microbubbles . Thus, the
exposed by ECMO . The prospect of providing a bridge to ,

decompression sickness and embolism ( thus leading to 10 have significant clinical implications . For example , acute

delivery of oxygen to a subject that is more effective and 15 associated with acute hypoxia in many subjects such as
SUMMARY OF THE INVENTION

The invention is a system and methods that circulates
oxygen microbubbles (OMBs) through a body cavity.
Although the invention is discussed in reference to the

intraperitorneal (IP ) cavity, the invention is also applicable

injury, which represent a significant percentage of those
requiring intensive care, may benefit from the delivery of
oxygen that offers minimally invasive extrapulmonary oxy

20 gen supplementation . Thus, ventilator-induced lung injury

may be minimized while avoiding critical hypoxia . Increas
ing systemic oxygen saturations may improve hypoxic pul
monary vasoconstriction and reduce pulmonary vascular

resistance in subjects with acute exacerbations of pulmonary

to other cavities of the subject such as the gastrointestinal 25 hypertension . Infants , for example , born with cyanotic con

(GI), pleural, cranial, vertebral, pericardial and other cavities
as more fully described below . The invention delivers OMBS
to the body via circulation through a body cavity using an
oxygen carrier and perfusion apparatus to provide for safe

genitalheart disease , could benefit from an effective delivery
of oxygen that may lessen their hypoxemia preoperatively ,
as well as during the early postoperative recovery period .

This therapy could also provide care for cases of irreversible
30 pulmonary failure and , hence , act as a bridge to lung
According to the invention , OMBs are designed for high
transplant. This work may be translated to a medical thera

and effective ventilation .

oxygen carrying capacity, high oxygen delivery rate and
sufficient stability for storage and transport. Direct systemic
oxygenation by injecting OMBs into the peritoneal space is

ECMO with a less - invasive method of ventilation .

peutic device with the aim of replacing or augmenting
According to the invention, OMBs are injected into a

The procedure and apparatus for circulating OMBs through

absorb carbon dioxide , followed by a saline flush to remove

therapy precludes the need for an extracorporeal loop to

OMBs into the cavity . This process cycle is repeated as

circulate blood , thus potentially circumventing the compli-

necessary. In the alternative, OMBs may be continuously

sented by ECMO.
Circulating OMBs through a body cavity requires less
equipment and technical expertise than initiating and main -

carbon dioxide and other gases .

a radical change from existing oxygen delivery platforms. 35 body cavity and allowed some time to deliver oxygen and

the peritoneal cavity is simple and straightforward , and the

them from the cavity , followed by another injection of

cations from thrombosis and intracranial hemorrhage pre - 40 circulated through the cavity to release oxygen and absorb

taining an ECMO circuit. Thus, body cavity ventilation

Since blood is oxygenated by OMBs administered
through the body cavity, the infusion of OMBs directly into
circulation is avoided . In addition , the upper size limit

therapy to medical facilities that presently lack the funding

occlusion . In certain embodiments , larger microbubbles

using OMBs may provide extrapulmonary ventilation (EV ) 45 (about 10 um diameter) is not required to avoid vascular

or highly trained personnel required for operating an ECMO

system .
By circulating OMBs in the body cavity , oxygen and

(about 10 -25 um diameter ) can be perfused through the body
cavity without fear of occlusion because they are separated

by gas-permeable membranous tissue from the intravascular

carbon dioxide exchange occurs across the peritoneum , the 50 space . Thus , the effects of larger microbubble size distribu

membrane of the abdominal cavity . Additionally, unlike IV

tions on microbubble suspension viscosity and oxygen

injection of microbubbles which cannot remove carbon

release rate (at equivalent volume fraction ) may be mea

dioxide , a body cavity injection and circulation of OMBS

sured . According to the invention , microbubbles may be

according to the invention can beneficially remove carbon between 1- 25 um in diameter with larger microbubbles
dioxide. Additionally , the IP injection of OMBs, for 55 being about 9 - 21 um in diameter and smaller microbubbles
example , is not subject to a strict upper limit of the

being about 1 - 8 um in diameter. However, it is contemplated

microbubble size and volume fraction since the

that microbubbles may be between 1 - 100 um in diameter

microbubbles are injected into the IP space (not the vascu

and even between 1 - 500 um in diameter. In addition , mix

lature ) and can thus easily be removed . This provides

tures of microbubbles may comprise microbubbles of dif

oxygen to a subject , for example after it experiences a right 60 ferent sizes . The sizes of the OMBs contained within any

pneumothorax . This significantly extends life in a subject

with an acute lung injury hypoxemia or similar situation in
which the lung function is sub -optimal.
Direct systemic ventilation by circulating OMBs through

one mixture may be only smaller microbubbles , only larger

microbubbles or a combination of both smaller and larger
microbubbles .
In embodiments in which a perfusate is administered , the

the body cavity space is a radical change from existing 65 perfusate may be about 60 % , 65 % , 70 % , 75 % , 80 % , 85 % ,
oxygen delivery platforms. For example , the invention may
90 % , or 95 % . In certain other example embodiments , the
be used to supplement ventilation in cases of airway failure , OMB perfusate may be between 10 % -90 % .

US 10 ,124 , 126 B2
One advantage of the invention over previously developed methods for extrapulmonary respiration is that the
invention delivers an adequate supply of oxygen , provides

a supply device 106 through the subject's body cavity 104
by a pump device 108 . As OMBs from the supply device 106
are pumped into the body cavity 104 of the subject 102 ,

long - term safety for the subject, and is cost-effective .
waste is simultaneously removed from the subject and
One advantage of the invention is that problems associ- 5 dispensed to the waste receptacle 110 . The monitoring of
ated with ECMO are addressed and have the potential to several life sustaining data is performed with sensors 112

significantly increase survivability of reversible pulmonary connected to the subject 102 and the monitoring device 114 .
Data include, for example , intra - abdominal pressure . The
disease, chronic lower respiratory disease , accidents, influ
intra -abdominal pressure is measured to avoid high internal
enza and pneumonia, airway failure , lung injury, respiratory 10 pressures that could damage the body 's internal organs .
failure caused by pathologies and dysfunctions such as heart
distress syndrome, and other causes . In addition , the inven

tion may help subjects survive avian flu and severe acute
respiratory syndrome (SARS ).

Other advantages of the invention include : reduced

Other data that may also be monitored include blood gas

levels of oxygen and carbon dioxide, heart pulse , blood
pressure , heart ejection faction and similar cardiac data . The

thrombogenic and immunogenic effects owing to lack of 15 monitoring device 114 transmits the data to a computer
direct contact with blood , reduced risk of embolism by the device 116 where the data is processed , for example , tabu
lated into a database, analyzed , and/or used to provide

OMBs or their lipid remnants because they are not in

feedback to the supply device 106 , for example to adjust the
circulation , and the possibility of an input/ output line to
amount of OMB delivered to the subject 102 . It is also
remove carbon dioxide in addition to providing oxygen .
An additional advantage of the invention is stability of the 20 contemplated that the supply device 106 transmits informa
OMBs. OMBs are stable at high volume fractions > 90 % )
tion to the computer device 116 for processing, for example ,
to adjust the data the sensors 112 monitor.
for several weeks in refrigerated storage.
FIG . 2 illustrates an example embodiment of a supply
Another advantage is that OMBs administered intrave
nously (< 70 vol % ) possess a rapid dissolving property and device 200 according to the invention . The supply device
release of oxygen in the presence of oxygen - deficient media 25 200 includes a reaction chamber 202 with inlets for a lipid
in vitro .

solution 204 , and oxygen gas 206 . The lipid solution 204 and

Additionally, OMBs according to the invention assist in

oxygen gas 206 are mixed to create a mixture 207, which is

further sustaining life during 15 minutes of complete tra

then cooled . The mixture 207 is cooled using material such

cheal occlusion in vivo . Thus, OMBs are a promising as air or liquid passing through an inlet 208 and outlet 210 .
30 In this process , a mix 212 of microbubbles and foam is
platform for non - extracorporeal oxygen delivery .
These and other features , aspects , and advantages of the created . The microbubbles and foam mix 212 is passed to a
invention will become better understood with regard to the collection container 220 . A solution 214 , such as saline , is
following description , appended claims, and accompanying purged into the collection container 220 to combine with the

microbubbles and foam mix 212 . The collection container
drawings.
220 includes a vent 216 for the discharge of gas . As the
BRIEF DESCRIPTION OF THE DRAWINGS
microbubbles and foam mix 212 combine with solution 214 ,
ambient gas is vented 216 and the foam 218 separates from
FIG . 1 illustrates an example embodiment of the ventila
the microbubbles 219 . The microbubbles 219 are then
collected in a syringe 222 , centrifuged and stored for future
tion system according to the invention .
FIG . 2 illustrates an example embodiment of a supply 40 use .
FIG . 3 illustrates one embodiment of a ventilation system
device according to the invention .
FIG . 3 illustrates one embodiment of a ventilation system
300 used in the delivery of oxygen to a subject according to
used in the delivery of oxygen to a subject according to the the invention . In this example embodiment, a subject 301
has a right pneumothorax 302. Cardiac arrest eventually
invention .
FIG . 4 illustrates another embodiment of a ventilation 45 follows a right pneumothorax and is caused by lack ofblood
system used in the delivery of oxygen to a subject according oxygen (hypoxemia ) and by elevated carbon dioxide levels
and subsequent low blood pH (acidosis) that result from
to the invention .
FIG . 5 illustrates an exemplary computer system accord - pulmonary failure . To keep the subject alive longer while
life -saving treatment can be administered , the ventilation
ing to the invention .

FIG . 6 illustrates an embodiment of the control scheme to 50 system 300 according to the invention is employed . A small
monitor the perfusion ofOMBs during delivery of oxygen to
incision is made into the abdomen of the subject 301 to give
access to the IP cavity. Oxygen microbubbles from the
a subject according to the invention .
FIG . 7 illustrates a graph of survival rates over time for supply device 304 are circulated into the IP cavity though a
test subjects with a pneumothorax model and intraperitoneal supply tube 308 with a peristaltic pump 306 . Additionally a
injection of oxygen microbubbles compared to saline injec - 55 scavenge tube 310 is used to remove fluid waste 312 , which
may be controlled by a valve 314 .
tion according to the invention .
FIG . 8 illustrates a graph of survival rates over time for
The effectiveness of IP extrapulmonary respiration is
test subjects with an asphyxiation model and pleural injec
established by measuring and monitoring several life sus
tion of oxygen microbubbles compared to saline injection
taining data . Intra -abdominal pressure may be measured at
60 the supply tube 308 inlet. This is measured to avoid high
according to the invention .
internal pressures that could damage the body 's internal
DETAILED DESCRIPTION OF EXAMPLE
organs. The blood gas levels of oxygen and carbon dioxide ,
heart pulse , blood pressure, heart ejection faction . Similar
EMBODIMENTS
cardiac data may be measured with a paw cuff pulse 316 or
FIG . 1 illustrates an example embodiment of the ventila - 65 similar medical device and perform periodic blood draws.
tion system 100 . In this example embodiment, a subject 102
Additionally drug dosage in the blood may be measured

is treated with oxygen microbubbles (OMB ) dispensed from

through a catheter 318 .Measuring and monitoring these and
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other life sustaining data may be performed with a monitoring device 320 and viewed on a monitor of a computer

device 322.

for example , a modem , a network interface (such as an
Ethernet card or Ethernet cable ), a communication port, a
PCMCIA slot and card, wired or wireless systems (such as

In an alternate embodiment, ventilation is performed
Wi- Fi, Bluetooth , Infrared ), local area networks, wide area
through the gastrointestinal (GI) space . The system setup for 5 networks , intranets , etc .
perfusing the GI is identical to that shown in FIG . 3 with the
It is contemplated that the main memory 508 , secondary

exception that the small intestine is resected at the duode

num and distal ileum with the mesentery left intact. The

memory 510 , communication interface 516 , or a combina

tion thereof, function as a computer usable storage medium ,

supply tube is inserted into the resected duodenum , the
to as a computer readable storage
scavenge tube is inserted into the resected distal ileum , and 10 otherwise, to referred
store and/ or access computer software including
microbubbles from the supply device are pumped into and medium
computer instructions . Certain embodiments of a computer
through the entire length of the small bowel.
readable
storage medium do not include any transitory
FIG . 4 illustrates another embodiment of a ventilation
signals
or
waves. For example , computer programs or other
system 400 used in the delivery of oxygen to a subject

may be loaded into the computer device 500
according to the invention . In this example embodiment, a 15 instructions
subject 402 is connected to the system 400 through its such as through a removable storage device , for example , a
pleural cavity 404 with an inlet/outlet tube 406 . The inlet/ floppy disk , ZIP disks, magnetic tape, portable flash drive ,
outlet tube 406 allows the subject 402 to receive oxygen optical disk such as a CD orDVD or Blu -ray, Micro - Electro
microbubbles from a supply device 410 through a pump 412 . Mechanical Systems (MEMS), nanotechnological system .
The microbubbles are warmed using fluid warmer device 20 Specifically , computer software including computer instruc
414 .
tions may be transferred from the removable storage unit
The supply device 410 includes an oxygen tank 416
connected to an oxygen inlet 418 that prevents the supply
device 410 from pressurizing while OMBs are pumped into

514 or hard disc unit 512 to the secondary memory 510 or
through the communication infrastructure 504 to the main
memory 508 of the computer device 500 .

the subject 402 . There is additionally an oxygen vent 420 to 25 Communication interface 516 allows software, instruc
assist in maintain ambient pressure in the supply device 410 .
tions and data to be transferred between the computer device

The inlet/outlet tube 406 additionally allows for an expul-

500 and external devices or external networks. Software ,

sion of waste from the subject 402 from the pleural cavity

instructions, and/ or data transferred by the communication

404 . The expulsion ofwaste may be controlled by a solenoid

interface 516 are typically in the form of signals that may be

valve 422 , which allows the waste to drain into a waste 30 electronic, electromagnetic , optical or other signals capable
receptacle 424 . As this procedure of OMB injection is of being sent and received by the communication interface

occurring, the subject 's vital data is monitored with a

516 . Signals may be sent and received using wire or cable ,

number of health sensors 426 that are connected to a

fiber optics , a phone line , a cellular phone link , a Radio

monitoring device 428 . Additionally , pressure may be moni-

Frequency (RF ) link , wireless link , or other communication

pressure sensor 430 may be connected to a computer device

Computer programs, when executed , enable the computer

tored by a pressure sensor 430 . Health sensors 426 and 35 channels .

432 thatmay tabulate the data into a database , analyze the device 500, particularly the processor 506 , to implement the
data , and /or used the data to provide feedback to one or more methods of the invention according to computer software
parts of the system 400. As an example , the machine including instructions.
computer device 432 may be connected to the supply device 40 The computer device 500 described herein may perform
410 to monitor and/or automate the injection time or quan any one of, or any combination of, the steps of any of the
tity of OMBs.
methods presented herein . It is also contemplated that the
FIG . 5 illustrates an exemplary computer device 500 that methods according to the invention may be performed
may be used to implement the methods according to the automatically, or may be invoked by some form of manual
invention . One or more computer systems 500 may carry out 45 intervention .
the methods presented herein as computer code . Computer
The computer device 500 of FIG . 5 is provided only for
device 500 includes an input/output display interface 502

purposes of illustration , such that the invention is not limited

connected to communication infrastructure 504 — such as a

to this specific embodiment . It is appreciated that a person

bus— that forwards data such as graphics, text, and infor -

skilled in the relevant art knows how to program and

mation , from the communication infrastructure 504 or from 50 implement the invention using any computer system .

a frame buffer ( not shown ) to other components of the
computer device 500 . The input/output display interface 502
may be , for example , a keyboard , touch screen , joystick ,

The computer device 500 may be a handheld device and
include any small -sized computer device including, for
example , a personal digital assistant (PDA ), smart hand- held

trackball, mouse, monitor, speaker, printer, Google Glass®
computing device , cellular telephone, or a laptop or netbook
unit, web camera, any other computer peripheral device, or 55 computer, hand held console or MP3 player, tablet, or
any combination thereof, capable of entering and /or viewing

data .

Computer device 500 includes one or more processors

506 , which may be a special purpose or a general-purpose

similar hand held computer device , such as an iPad® , iPad
Touch® or iPhone® .
FIG . 6 is an example embodiment of the control system

schematic that may be implemented at the solenoid valve to

digital signal processor configured to process certain infor- 60 control the cavity pressure between the subject and the waste

mation . Computer device 500 also includes a main memory

508 , for example random access memory (RAM ), read -only

memory (ROM ), mass storage device , or any combination
thereof. Computer device 500 may also include a secondary

receptacle . Through monitoring the cavity pressure , the

solenoid valve may be opened to relieve and lower pressure

within the cavity or may be closed to increase pressure

within the cavity . The opening and closing of the valve may

memory 510 such as a hard disk unit 512 , a removable 65 be automated with use of the control system implemented to
storage unit 514 , or any combination thereof. Computer
the computer device or may be manual with the control
device 500 may also include a communication interface 516 , system providing an alarm .
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10
determine the oxygen -release rate (ng/s ). The oxygen -re

lease rate is compared for microbubbles of two different size
distributions ( 1 - 10 um diameter vs. 10 -20 um diameter ),
each at three different OMB flow rates ( 1 , 10 and 20
molar ratio of distearoyl phosphatidylcholine (DSPC ) to 5 mL/min ) and three different volume fractions (50 , 70 and

OMB Production:
In an example embodiment, lipids are mixed at a 9 : 1

poly (ethylene glycol)-40 stearate (PEG40S ) in saline and
sonicated at low power to create the small, unilamellar

90 % ).

IP Ventilation of Rat Model In Vivo :

liposomes. O , and liposomes (5 mg/mL ) are then combined

Using the system according to the invention , rats expe

in the reaction chamber , where a high - power, 1/2 -inch diam -

rienced a right pneumothorax after generally anesthetized by

eter, 20 -kHz sonicator tip emulsifies the oxygen gas into 10 isoflurane ( 5 % induction to effect ) followed by sodium

micrometer -scale spheres around which phospholipid

pentobarbital ( 50 mg/ kg , intramuscular ). Anesthesia depth is

adsorbs from vesicles and micelles and self-assembles into

monitored and OMB perfusate is pumped into the IP space

a highly condensed ( solid ) monolayer coating. OMBs are
separated from macroscopic foam in a subsequent flotation

through a small incision in an upper quadrant of the abdo
men . The IP incision is sutured / glued around the supply and

container and collected in syringes and centrifuged (500 g 15 scavenger tubing to form a seal. Intra -abdominal pressure is
for 3 min ) to form concentrated OMBs. The sonication
maintained at 8 mmHg through the use of a fluidic control

chamber and container are jacketed with circulating coolant

to maintain a constant temperature of 20° C .
OMBs are fabricated for live animal testing , in which four

solenoid valve and pressure catheter at the scavenger tube

exit. Intra -abdominal pressure of 8 mmHg is used because it
is typical of human insufflation pressures during laparo

factors are investigated : perfusate , perfusion rate , motility 20 scopic surgery. Cardiac arrest will eventually follow pneu

drug, and method (IP or GI) . OMB perfusate at 70 % and

mothorax and is caused by lack of blood oxygen (hypox

90 % indicate the volume fraction of oxygen in the OMB
emulsion . At 70 % , the OMB emulsion 's rheological prop
erties are similar to saline and the perfusate is expected to
circulate well through the IP space .
25

emia ) and by elevated carbon dioxide levels and subsequent
low blood pH (acidosis ), which result from pulmonary

OMB Size Distribution Measurements:

failure . The effectiveness of IP EV is established from

periodic tail-vein blood draws (5 -minute intervals, total
draws less than 1 % body weight) and measurement of blood

OMB size distribution is varied by choosing different
residence times in the flotation container (e.g., 153 min for

oxygen , carbon dioxide, pH , osmolality levels , and general
blood chemistry .

cytometry scatter , and optical microscopy . Alternatively ,
size selection may be unnecessary and may be removed
from the process. OMB volume fraction is measured , for

perfusate at 70 % and 90 % indicate the volume fraction of
oxygen in the OMB emulsion . At 50 % , the OMB emulsion ' s
rheological properties are similar to saline . In certain other

tion is measured over time to investigate coalescence , Ost

ments, an OMB concentration of about 10 % - 90 % may be

a 10 -um diameter cut-off ; 38 min for a 20 - um diameter
Fluids used as a perfusate are saline as a control or a
cut -off ). Size distribution is measured , for example , by 30 solution with an OMB concentration of 70 % or 90 % and
electrical capacitance, light extinction /scattering, flow
dispensed at fluid flow rates of 0 , 8 , and 16 mL /min . OMB

example , by gravimetric analysis and varied from 50 - 90 vol 35 example embodiments , an OMB concentration between
% by dilution with saline. Microbubble size and concentra 60 % - 95 % may be used . In certain other example embodi

wald ripening and stability in storage .

used . At 90 % volume fraction , the OMBs ability to circulate
in the IP space degrades due to increased viscosity, but
OMB Dissolution in Oxygen -Depleted Media :
Clinical translation of OMB technology to treat hypox - 40 oxygen content is enhanced . It was calculated that perfusing
emia requires quantitativemodeling of the pharmacokinetics
OMBs at 8 mL/min provides sufficient oxygen capacity for
of oxygen delivery, whether administered through the IV , IP a 400 g rat. Perfusing OMBs at 8 mL min - 1 provides
or GI route. A model for single OMB dissolution in an sufficient oxygen capacity considering a 400 g rat. Perfusion
oxygen - depleted medium with the presence of venous gases at a higher rate (16 mL min - -) and introducing a stagnant
( 30 mmHg 0 , 600 mmHg N , and 50 mmHg CO ) has been 45 OMB bolus ( 0 mL min ) . The motility enhancing drug

developed . Results demonstrate the microbubble exhibits
two dissolution regimes. First, rapid dissolution occurs as 02

ghrelin is administered (200 mg kg- dose ) in half of the
tests via the tail vein catheter 30 minutes prior to anesthe
dissolves out, even as N , and CO , counter - diffuse into the tization .
bubble . Second , 0 , is depleted and slower dissolution occurs
IP Ventilation of Rabbit Model In Vivo:
as N2 and CO2 dissolve out. For a 20 -um diameter 50 Male New Zealand White rabbits (n = 13 , m = 2.260 + 0 .196

microbubble ,most of the oxygen is released within 10 s. The kg ) were weighed and anesthetized by 5 % isoflurane gas by
bubble then carries N , and CO2 (therefore acting as a blood nose cone to effect. Rabbits were then intubated with an
gas scrubber for non -oxygen species ).
endotracheal tube and laid in the supine position on a
The simulation results indicate that the highest rate of warming pad set at 38° C . to maintain body temperature . The
oxygen transfer for the suspension occurs with the minimal 55 abdomen of the rabbit was shaved , divided into quadrants
OMB residence time in the IP space . Thus , rapid mixing with a marker, and sterilized . A veterinary monitor was used
should provide high mass transfer coefficients for both OMB to monitor and record vitals via two sensors placed rectally ;
oxygen release and oxygen transfer in the fluid medium to
a pulse oximetry sensor was used to measure pulse rate and
the parietal peritoneum and visceral peritoneum membranes .
arterial oxygen hemoglobin saturation ( SpO2), and a tem
The results also indicate that oxygen -release rate increases 60 perature probe was used for measuring body temperature.
substantially for larger microbubbles . It is expected that
The rabbit was given an intramuscular injection of ket

mixing conditions (i.e ., viscosity ) will dominate the rate of
oxygen release .

Oxygen -Release Rate Measurements:

amine -xylazine ( 35 -5 mg/kg) and then gradually weaned off
isoflurane and allowed to breathe room air . A small incision

was made into the abdomen to allow access for placement of

Three trials ( three measurements per trial ) are taken for 65 infusion and drainage tubing (3 .2 mm inner, 4 .8 mm outer
each OMB flow rate and size distribution . Oxygen content diameter, Tygon ) in the intraperitoneal cavity and then
is plotted versus time, and the linear regime is used to sutured closed . A 12 G indwelling catheter and a 14 G needle
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connected to pressure transducers were inserted into the IP

cavity for measuring intra - abdominal pressure via a data
acquisition and custom control system . The control system
was designed to use IA pressure and a solenoid fixed to the
drainage line to regulate the volume of perfusate adminis - 5

s haved , divided into quadrants with a marker, and sterilized .
A veterinary monitor was used to monitor and record vitals
via two sensors placed rectally ; a pulse oximetry sensor was
used to measure pulse rate and arterial oxygen hemoglobin
saturation ( Spo , ), and a temperature probe was used for

tered into the cavity .
measuring body temperature. The rabbit was given an intra
Perfusate was pumped through a fluid warmer set at 40 .4° muscular injection of ketamine- xylazine (35- 5 mg/kg) and
C . and into the IP space with a peristaltic pump at 80 mL/min
then gradually weaned off isoflurane and allowed to breathe
for 3 minutes and then at dose of 12 .6 mL /min *kg thereafter.
room
air. A small incision was made into the abdomen to
At this time, the endotracheal tube was hermetically sealed 10
to prevent oxygen intake and simulate complete lung failure . allow access for placement of infusion and drainage tubing
The fluids used as a perfusate were oxygenated saline for the
control group and OMBs for the experimental group . The

(3 .2 mm inner, 4 .8 mm outer diameter, Tygon ) in the pleural
cavity and then sutured closed . A 12 G indwelling catheter

survival data for rabbits using saline survived 6 . 9 + 0 .6 min

and a 14 G needle connected to pressure transducers were

tube had been sealed : The outlier 72 minute survival time

6 . The control system was designed to use IA pressure and

utes. The OMB treated rabbits survived on average for 18 15 inserted into the pleural cavity formeasuring pressure via a
minutes and one outlier lived for 72 minutes after the trachea data acquisition and custom control system as shown in FIG .
rabbit had successful circulation and IA pressure below 8

a solenoid fixed to the drainage line to regulate the volume
of perfusate administered into the cavity .
mmHg.
20 Perfusate was pumped through a fluid warmer set at 40.4°
GI Ventilation of Rat Model In Vivo :
The test setup for perfusing the GI is identical to that for
C . and into the pleural space . At this time, the endotracheal
perfusing the IP except that the small intestine is resected at tube was hermetically sealed to prevent oxygen intake and
the duodenum and distal ileum (with the mesentery left
intact). The supply tube is inserted into the resected duode-

simulate complete lung failure. The fluids used as a per
fusate were oxygenated saline for the control group and

num , the scavenge tube is inserted into the resected distal 25 OMBs for the experimental group. The survival data for
ileum , and perfusate is pumped into and through the entire rabbits using saline under a saline bolus or saline perfusion
length of the small bowel. Saline with neutral oxygen injection survived an average of seven minutes. The OMB
tension with respect to atmosphere is used as a third per perfusion treated rabbits survived on average for 15 minutes
fusate to provide a control for all experiments . Six rats are and OMB bolus treated rabbits survived on average for 17 . 5
tested at the given OMB perfusion rate of 8 and 16 mL/min 30 minutes as shown in FIG . 8 .
While the disclosure is susceptible to various modifica
flow rates and the internal pressure over time was measured

to find suitable conditions for infusion and scavenging.

tions and alternative forms, specific exemplary embodi

Perfusing OMBs at 8 mL min -1 in 400 g rats with a right
7 illustrates a graph of survival rates over time for tact
test

the contrary, the intention is to cover all modifications,
equivalents, and alternatives falling within the scope of the
disclosure as defined by the appended claims.

re never surpasses the ments of the invention have been shown by way of example
Results show that internal pressure
upper limit of 8 mmHg and the system perfuses saline at the in the drawings and have been described in detail . It should
desired rates while maintaining physiological pressure lev - 35 be understood , however, that there is no intent to limit the
disclosure to the particular embodiments disclosed , but on
els in the phantom abdomen .

pneumothorax survival rates are promising over time. FIG .

subjects with a pneumothorax model and intraperitoneal 40

injection of oxygen microbubbles compared to saline injec

What is claimed is:

and elevated carbon dioxide levels and subsequent low

cooling the mixture using a cooling material passing

tion according to the invention . The fluids used as perfusate
were (1 ) saline as a control or (2 ) a solution with an OMB
concentration of ~ 50 vol % . Intra - abdominal pressure was

1. A method for administering oxygen to a subject,
comprising the steps of:
providing a supply device containing a reaction chamber;
measured at the supply tube inlet to avoid high internal 45 mixing in the reaction chamber a lipid solution received
pressures that could damage internal organs or the IP cath
from a first inlet of a supply device and an oxygen gas
eter seal. Cardiac arrest eventually follows a right pneumo
received from a second inlet of the supply device to
thorax and is caused by lack of blood oxygen (hypoxemia )
form a mixture;
blood pH ( acidosis ), which result from pulmonary failure . 50
As shown in FIG . 7 , saline control specimens survived for

an average of ~ 14 .1 minutes after right pneumothorax in the

through the supply device from a third inlet to an outlet,
said cooling step creating in the reaction chamber a mix

of a plurality of oxygen microbubbles and a foam ;

presence of saline . In comparison , the specimen injected
with OMBs survived for an average of - 83 .3 minutes after

transporting the mix to a collection container ;
adding a saline solution to the collection container to

ment in survivability in comparison to the controls (p < 0 .5 ;

foam ;
venting from the collection container a gas formed during
said adding step ;

right pneumothorax , which represents a ~ 8 - fold improve - 55

Gehan -Breslow -Wilcoxon Test). The effectiveness of IP
ventilation was established by measuring saturated arterial

separate the plurality of oxygen microbubbles and the

oxygen fraction (SAO2). Results demonstrate that cardiac

collecting the plurality ofmicrobubbles into a syringe ;

arrest in hypoxemic rodents is significantly delayed by 60

delivering by a pump device from the syringe one ormore

intraperitoneal administration of OMBs.
Pleural Cavity Ventilation of Rabbit Model In Vivo :

monitoring by a monitoring device including one or more

Male New Zealand White rabbits were weighed and
Rabbits were then intubated with an endotracheal tube and 65
anesthetized by 5 % isoflurane gas by nose cone to effect.

laid in the supine position on a warming pad set at 38° C . to
maintain body temperature. The abdomen of the rabbit was

oxygen microbubbles to a body cavity of the subject;

sensors data resultant from delivery of the one or more
oxygen microbubbles to the body cavity ;

receiving by a computer device the data ; and

processing the data by the computer device to measure
effectiveness of extrapulmonary respiration .
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2 . The method for administering oxygen to a subject

according to claim 1 further comprising the step of receiving
by a waste receptacle waste from the subject.

3 . The method for administering oxygen to a subject
according to claim 1 , wherein the data includes one or more 5

of the following: intra - abdominal pressure , blood gas levels
of oxygen , blood gas levels of carbon dioxide , heart pulse ,
blood pressure , and heart ejection faction .

4 . The method for administering oxygen to a subject

according to claim 1 further comprising the step of using by 10

the computer device the processed data to adjust the delivery
of the one or more oxygen microbubbles to the subject.
5 . The method for administering oxygen to a subject

according to claim 1, wherein the one or more oxygen
monolayer.
6 . The method for administering oxygen to a subject
according to claim 1, wherein each microbubble is 10 - 25
micrometers (um ) in diameter.
7. The method for administering oxygen to a subject 20
according to claim 1 , wherein each microbubble is 1 - 8
micrometers (um ) in diameter.

microbubbles comprise a shell composed of a phospholipid 15

8 . The method for administering oxygen to a subject
according to claim 1 , wherein the body cavity of the subject
of the delivery step includes one or more of the following 25
cavities: intraperitoneal, gastrointestinal, pleural, cranial,

vertebral, and pericardial.

14

